NASDAQ:VKTX

Viking Therapeutics Competitors

$5.87
-0.22 (-3.61 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$5.70
Now: $5.87
$6.08
50-Day Range
$5.74
MA: $6.37
$7.05
52-Week Range
$5.22
Now: $5.87
$10.09
Volume1.25 million shs
Average Volume1.37 million shs
Market Capitalization$453.03 million
P/E RatioN/A
Dividend YieldN/A
Beta2.02

Competitors

Viking Therapeutics (NASDAQ:VKTX) Vs. MORF, PAND, FPRX, CYTK, AMRX, and IRWD

Should you be buying VKTX stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Viking Therapeutics, including Morphic (MORF), Pandion Therapeutics (PAND), Five Prime Therapeutics (FPRX), Cytokinetics (CYTK), Amneal Pharmaceuticals (AMRX), and Ironwood Pharmaceuticals (IRWD).

Viking Therapeutics (NASDAQ:VKTX) and Morphic (NASDAQ:MORF) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, dividends, analyst recommendations and risk.

Valuation and Earnings

This table compares Viking Therapeutics and Morphic's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viking TherapeuticsN/AN/A$-25,780,000.00($0.36)-16.31
Morphic$16.98 million105.26$-43,330,000.00($2.69)-20.48

Viking Therapeutics has higher earnings, but lower revenue than Morphic. Morphic is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Viking Therapeutics has a beta of 2.02, indicating that its share price is 102% more volatile than the S&P 500. Comparatively, Morphic has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500.

Institutional and Insider Ownership

54.1% of Viking Therapeutics shares are held by institutional investors. Comparatively, 61.5% of Morphic shares are held by institutional investors. 3.7% of Viking Therapeutics shares are held by company insiders. Comparatively, 39.5% of Morphic shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Viking Therapeutics and Morphic's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Viking TherapeuticsN/A-13.57%-13.14%
MorphicN/A-36.62%-20.69%

Analyst Recommendations

This is a breakdown of recent ratings for Viking Therapeutics and Morphic, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Viking Therapeutics00913.10
Morphic00203.00

Viking Therapeutics currently has a consensus target price of $16.4444, indicating a potential upside of 180.14%. Morphic has a consensus target price of $63.3333, indicating a potential upside of 14.98%. Given Viking Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Viking Therapeutics is more favorable than Morphic.

Summary

Viking Therapeutics beats Morphic on 10 of the 13 factors compared between the two stocks.

Viking Therapeutics (NASDAQ:VKTX) and Pandion Therapeutics (NASDAQ:PAND) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, institutional ownership and valuation.

Insider & Institutional Ownership

54.1% of Viking Therapeutics shares are owned by institutional investors. Comparatively, 35.7% of Pandion Therapeutics shares are owned by institutional investors. 3.7% of Viking Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Viking Therapeutics and Pandion Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Viking TherapeuticsN/A-13.57%-13.14%
Pandion TherapeuticsN/AN/AN/A

Earnings & Valuation

This table compares Viking Therapeutics and Pandion Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viking TherapeuticsN/AN/A$-25,780,000.00($0.36)-16.31
Pandion Therapeutics$970,000.001,827.25$-21,880,000.00N/AN/A

Pandion Therapeutics has higher revenue and earnings than Viking Therapeutics.

Analyst Ratings

This is a breakdown of recent recommendations for Viking Therapeutics and Pandion Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Viking Therapeutics00913.10
Pandion Therapeutics02202.50

Viking Therapeutics currently has a consensus target price of $16.4444, indicating a potential upside of 180.14%. Pandion Therapeutics has a consensus target price of $44.25, indicating a potential downside of 26.31%. Given Viking Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Viking Therapeutics is more favorable than Pandion Therapeutics.

Summary

Viking Therapeutics beats Pandion Therapeutics on 6 of the 10 factors compared between the two stocks.

Five Prime Therapeutics (NASDAQ:FPRX) and Viking Therapeutics (NASDAQ:VKTX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.

Insider & Institutional Ownership

67.3% of Five Prime Therapeutics shares are held by institutional investors. Comparatively, 54.1% of Viking Therapeutics shares are held by institutional investors. 6.4% of Five Prime Therapeutics shares are held by company insiders. Comparatively, 3.7% of Viking Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Five Prime Therapeutics and Viking Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Five Prime Therapeutics06202.25
Viking Therapeutics00913.10

Five Prime Therapeutics currently has a consensus target price of $30.7143, indicating a potential downside of 19.17%. Viking Therapeutics has a consensus target price of $16.4444, indicating a potential upside of 180.14%. Given Viking Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Viking Therapeutics is more favorable than Five Prime Therapeutics.

Profitability

This table compares Five Prime Therapeutics and Viking Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Five Prime Therapeutics-554.71%-75.84%-49.08%
Viking TherapeuticsN/A-13.57%-13.14%

Volatility & Risk

Five Prime Therapeutics has a beta of 4.4, suggesting that its stock price is 340% more volatile than the S&P 500. Comparatively, Viking Therapeutics has a beta of 2.02, suggesting that its stock price is 102% more volatile than the S&P 500.

Valuation & Earnings

This table compares Five Prime Therapeutics and Viking Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Five Prime Therapeutics$14.87 million119.01$-137,200,000.00($3.92)-9.69
Viking TherapeuticsN/AN/A$-25,780,000.00($0.36)-16.31

Viking Therapeutics has lower revenue, but higher earnings than Five Prime Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Five Prime Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Viking Therapeutics beats Five Prime Therapeutics on 10 of the 14 factors compared between the two stocks.

Cytokinetics (NASDAQ:CYTK) and Viking Therapeutics (NASDAQ:VKTX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, earnings, dividends and institutional ownership.

Institutional & Insider Ownership

97.1% of Cytokinetics shares are owned by institutional investors. Comparatively, 54.1% of Viking Therapeutics shares are owned by institutional investors. 6.4% of Cytokinetics shares are owned by company insiders. Comparatively, 3.7% of Viking Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Cytokinetics and Viking Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cytokinetics$26.87 million65.76$-121,690,000.00($2.11)-11.71
Viking TherapeuticsN/AN/A$-25,780,000.00($0.36)-16.31

Viking Therapeutics has lower revenue, but higher earnings than Cytokinetics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cytokinetics and Viking Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cytokinetics-209.88%-3,065.14%-36.39%
Viking TherapeuticsN/A-13.57%-13.14%

Risk & Volatility

Cytokinetics has a beta of 1.45, suggesting that its share price is 45% more volatile than the S&P 500. Comparatively, Viking Therapeutics has a beta of 2.02, suggesting that its share price is 102% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and target prices for Cytokinetics and Viking Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cytokinetics011002.91
Viking Therapeutics00913.10

Cytokinetics presently has a consensus price target of $33.6364, suggesting a potential upside of 36.18%. Viking Therapeutics has a consensus price target of $16.4444, suggesting a potential upside of 180.14%. Given Viking Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Viking Therapeutics is more favorable than Cytokinetics.

Summary

Viking Therapeutics beats Cytokinetics on 10 of the 14 factors compared between the two stocks.

Viking Therapeutics (NASDAQ:VKTX) and Amneal Pharmaceuticals (NYSE:AMRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, analyst recommendations, risk and dividends.

Profitability

This table compares Viking Therapeutics and Amneal Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Viking TherapeuticsN/A-13.57%-13.14%
Amneal Pharmaceuticals3.30%42.02%3.82%

Risk and Volatility

Viking Therapeutics has a beta of 2.02, indicating that its stock price is 102% more volatile than the S&P 500. Comparatively, Amneal Pharmaceuticals has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500.

Earnings & Valuation

This table compares Viking Therapeutics and Amneal Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viking TherapeuticsN/AN/A$-25,780,000.00($0.36)-16.31
Amneal Pharmaceuticals$1.63 billion1.09$-361,920,000.00$0.2721.81

Viking Therapeutics has higher earnings, but lower revenue than Amneal Pharmaceuticals. Viking Therapeutics is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

54.1% of Viking Therapeutics shares are held by institutional investors. Comparatively, 33.5% of Amneal Pharmaceuticals shares are held by institutional investors. 3.7% of Viking Therapeutics shares are held by insiders. Comparatively, 26.3% of Amneal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Viking Therapeutics and Amneal Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Viking Therapeutics00913.10
Amneal Pharmaceuticals01502.83

Viking Therapeutics presently has a consensus target price of $16.4444, indicating a potential upside of 180.14%. Amneal Pharmaceuticals has a consensus target price of $7.00, indicating a potential upside of 18.85%. Given Viking Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Viking Therapeutics is more favorable than Amneal Pharmaceuticals.

Ironwood Pharmaceuticals (NASDAQ:IRWD) and Viking Therapeutics (NASDAQ:VKTX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Valuation and Earnings

This table compares Ironwood Pharmaceuticals and Viking Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ironwood Pharmaceuticals$428.41 million3.99$21.50 million$0.5519.29
Viking TherapeuticsN/AN/A$-25,780,000.00($0.36)-16.31

Ironwood Pharmaceuticals has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings for Ironwood Pharmaceuticals and Viking Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ironwood Pharmaceuticals04102.20
Viking Therapeutics00913.10

Ironwood Pharmaceuticals presently has a consensus price target of $11.40, indicating a potential upside of 7.45%. Viking Therapeutics has a consensus price target of $16.4444, indicating a potential upside of 180.14%. Given Viking Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Viking Therapeutics is more favorable than Ironwood Pharmaceuticals.

Insider & Institutional Ownership

54.1% of Viking Therapeutics shares are owned by institutional investors. 2.4% of Ironwood Pharmaceuticals shares are owned by insiders. Comparatively, 3.7% of Viking Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Ironwood Pharmaceuticals and Viking Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ironwood Pharmaceuticals27.77%-240.80%27.05%
Viking TherapeuticsN/A-13.57%-13.14%

Risk and Volatility

Ironwood Pharmaceuticals has a beta of 1.46, indicating that its stock price is 46% more volatile than the S&P 500. Comparatively, Viking Therapeutics has a beta of 2.02, indicating that its stock price is 102% more volatile than the S&P 500.

Summary

Viking Therapeutics beats Ironwood Pharmaceuticals on 8 of the 14 factors compared between the two stocks.


Viking Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
MORF
Morphic
1.3$55.08-0.6%$1.79 billion$16.98 million-35.31Insider Selling
Decrease in Short Interest
Pandion Therapeutics logo
PAND
Pandion Therapeutics
1.0$60.05-0.0%$1.77 billion$970,000.000.00
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.4$38.00-0.0%$1.77 billion$14.87 million-14.18Increase in Short Interest
News Coverage
Cytokinetics logo
CYTK
Cytokinetics
1.7$24.70-0.7%$1.77 billion$26.87 million-12.93Insider Selling
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.8$5.89-0.2%$1.77 billion$1.63 billion14.37Analyst Report
Decrease in Short Interest
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$10.61-2.2%$1.71 billion$428.41 million15.38News Coverage
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.7$31.70-0.5%$1.68 billion$392.76 million13.15Analyst Upgrade
Analyst Revision
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$18.06-1.0%$1.64 billionN/A-6.43Increase in Short Interest
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$17.87-0.8%$1.63 billion$145.97 million-7.23
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$23.29-1.4%$1.60 billion$2.34 million-9.87
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$28.15-0.5%$1.60 billionN/A0.00Analyst Revision
News Coverage
Generation Bio logo
GBIO
Generation Bio
1.8$28.30-2.8%$1.60 billionN/A0.00Insider Selling
Increase in Short Interest
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$12.35-2.0%$1.57 billion$320,000.00-8.40News Coverage
uniQure logo
QURE
uniQure
1.7$34.07-4.1%$1.53 billion$7.28 million-9.04Insider Selling
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.2$24.95-4.0%$1.51 billion$175.34 million-14.68Analyst Downgrade
Analyst Revision
News Coverage
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.52-2.4%$1.50 billion$82.27 million-18.34
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.4$32.24-5.2%$1.50 billionN/A0.00Analyst Upgrade
News Coverage
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$41.84-3.6%$1.47 billionN/A0.00
OLMA
Olema Pharmaceuticals
1.6$36.14-2.1%$1.45 billionN/A0.00Increase in Short Interest
News Coverage
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.4$32.37-0.9%$1.45 billionN/A0.00Insider Selling
Increase in Short Interest
Endo International logo
ENDP
Endo International
1.3$6.26-3.4%$1.44 billion$2.91 billion-9.21
Cara Therapeutics logo
CARA
Cara Therapeutics
1.6$28.51-0.7%$1.42 billion$19.89 million-13.45Analyst Report
News Coverage
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$21.71-1.0%$1.42 billion$73.41 million-4.59
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$32.56-0.8%$1.41 billion$6.20 million-14.28News Coverage
Zymeworks logo
ZYME
Zymeworks
1.8$30.38-0.7%$1.40 billion$29.54 million-8.06Unusual Options Activity
Cassava Sciences logo
SAVA
Cassava Sciences
0.9$34.85-0.7%$1.39 billionN/A-145.21
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$26.68-1.3%$1.38 billion$4.23 million-19.76Increase in Short Interest
ATBPD
Antibe Therapeutics
0.1$3.57-0.3%$1.38 billion$7.51 million-5.95Gap Down
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$27.52-4.2%$1.38 billionN/A-2.98
Keros Therapeutics logo
KROS
Keros Therapeutics
1.6$56.67-12.0%$1.32 billionN/A0.00Increase in Short Interest
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$34.35-0.9%$1.26 billionN/A0.00Analyst Upgrade
News Coverage
Shattuck Labs logo
STTK
Shattuck Labs
1.5$30.01-5.6%$1.25 billionN/A0.00Analyst Report
Increase in Short Interest
Repare Therapeutics logo
RPTX
Repare Therapeutics
1.6$33.68-1.1%$1.25 billionN/A0.00
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$10.99-1.2%$1.24 billion$35.22 million-8.02News Coverage
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$15.89-1.6%$1.21 billion$4.23 million-8.88
Kronos Bio logo
KRON
Kronos Bio
1.7$21.56-0.7%$1.21 billionN/A0.00Insider Selling
Innoviva logo
INVA
Innoviva
1.4$11.90-0.1%$1.21 billion$261.02 million6.07
Avid Bioservices logo
CDMO
Avid Bioservices
1.7$19.16-1.7%$1.17 billion$59.70 million-191.60
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$26.55-0.3%$1.16 billion$230,000.00-12.35
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$37.01-0.0%$1.16 billionN/A-2.65
Mersana Therapeutics logo
MRSN
Mersana Therapeutics
1.2$16.65-3.7%$1.15 billion$42.12 million-12.33Unusual Options Activity
NKTX
Nkarta
1.8$34.87-5.2%$1.14 billionN/A0.00Increase in Short Interest
News Coverage
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.6$26.22-4.1%$1.14 billionN/A-8.83Insider Selling
Increase in Short Interest
Omeros logo
OMER
Omeros
1.4$18.37-0.2%$1.14 billion$111.81 million-7.72News Coverage
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.4$30.91-6.5%$1.13 billionN/A-17.17
Pliant Therapeutics logo
PLRX
Pliant Therapeutics
1.9$29.93-2.4%$1.07 billion$57.05 million0.00Insider Selling
News Coverage
Constellation Pharmaceuticals logo
CNST
Constellation Pharmaceuticals
1.2$22.29-4.5%$1.07 billionN/A-8.23Unusual Options Activity
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$15.63-5.2%$1.07 billionN/A-6.59
Arcturus Therapeutics logo
ARCT
Arcturus Therapeutics
1.6$40.33-2.0%$1.06 billion$20.79 million-13.91News Coverage
Zogenix logo
ZGNX
Zogenix
1.7$19.00-3.5%$1.06 billion$3.65 million-2.00Analyst Upgrade
News Coverage
This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.